Despite enormous advancements in medical science and technology, there are few effective treatments for cancer. Major causes of disability and death include the metastasis and recurrence of cancer. Because conventional cancer treatments have many drawbacks, cancer nanomedicine, also known as cancer nanotechnology, has emerged as a more precise and benign cancer treatment option. Despite enormous advancements in medical science and technology, there are few effective treatments for cancer. Major causes of disability and death include the metastasis and recurrence of cancer. Because conventional cancer treatments have many drawbacks, cancer nanomedicine, also known as cancer nanotechnology, has emerged as a more precise and benign cancer treatment option. Novel nanomaterials stabilised by biomolecules have become well-known next-generation materials in recent years. Nanotechnology advancements have made nanoparticles possible, opening the door to viable treatments for blood cancer. The properties of nanoparticles can be changed. They can be made to target specific areas and regulate the dosage of medication that enters those areas. Nanoparticles may therefore increase treatment effectiveness while minimising side effects. In order to get nanoparticle therapy to the bedside, several experimental challenges must be solved. Therefore, it is critical to create potent formulations that can solve the aforementioned issues and provide precise tumour targeting without compromising the survival of healthy tissue. To demonstrate the promise of nanoparticles in the treatment of leukaemia, myeloma, and lymphoma, this review primarily focuses on the highlights of recent research progress employing nanoparticles to deliver diverse blood cancer therapeutic medications. We conclude by looking at future directions and potential projects for therapeutic nanomedicine research.
